Investigational drugs for atopic dermatitis

References

• Leung AK, Hon KL, Robson WL. Atopic dermatitis. Adv Pediatr. 2007;54:241–273.
   PubMedGoogle Scholar
• Leung DY. Atopic dermatitis: the skin as a window into the pathogenesis of chronic allergic diseases. J Allergy Clin Immunol. 1995;96:302–318.
   PubMed Web of Science ®Google Scholar
• Leung AKC, Barber KA. Managing childhood atopic dermatitis. Adv Ther. 2003;20:129–137.
   PubMed Web of Science ®Google Scholar
• Leung DY, Jain N, Leo HL. New concepts in the pathogenesis of atopic dermatitis. Curr Opin Immunol. 2003;15:634–638.
   PubMed Web of Science ®Google Scholar
• Leung DY, Bieber T. Atopic dermatitis. Lancet. 2003;361:151–160.
   PubMed Web of Science ®Google Scholar
• Leung DY, Boguniewicz M, Howell MD, et al. New insights into atopic dermatitis. J Clin Investig. 2004;113:651–657.
   PubMed Web of Science ®Google Scholar
• Sehra S, Tuana FM, Holbreich M, et al. Scratching the surface: towards understanding the pathogenesis of atopic dermatitis. Crit Rev Immunol. 2008;28:15–43.
   PubMed Web of Science ®Google Scholar
• Leung A, Hon K. Atopic dermatitis: a review for the primary care physician. Vol. 2011. Hauppauge, N.Y.: Nova Science Publishers; 2011.
   Google Scholar
• Grillo M, Gassner L, Marshman G, et al. Pediatric atopic eczema: the impact of an educational intervention. Pediatr Dermatol. 2006;23:428–436.
   PubMed Web of Science ®Google Scholar
• Williams HC. Is the prevalence of atopic dermatitis increasing? Clin Exp Dermatol. 1992;17:385–391.
   PubMed Web of Science ®Google Scholar
• Simpson EL, Hanifin JM. Atopic dermatitis. J Am Acad Dermatol. 2005;53:115–128.
   PubMed Web of Science ®Google Scholar
• Leung R, Wong G, Lau J, et al. Prevalence of asthma and allergy in Hong Kong schoolchildren: an ISAAC study. Eur Respir J. 1997;10:354–360.
   PubMed Web of Science ®Google Scholar
• Leung DY, Nicklas RA, Li JT, et al. Disease management of atopic dermatitis: an updated practice parameter. Joint task force on practice parameters. Ann Allergy, Asthma, Immunol. 2004;93:S1–21.
   PubMed Web of Science ®Google Scholar
• Simpson EL. Atopic dermatitis: a review of topical treatment options. Curr Med Res Opin. 2010;26:633–640.
   PubMed Web of Science ®Google Scholar
• Shaw TE, Currie GP, Koudelka CW, et al. Eczema prevalence in the United States: data from the 2003 National Survey of Children’s Health. J Invest Dermatol. 2011;131:67–73.
   PubMed Web of Science ®Google Scholar
• Bufford JD, Gern JE. The hygiene hypothesis revisited. Immunol Allergy Clin North Am. 2005;25:247–2vi.
   PubMed Web of Science ®Google Scholar
• Flohr C, Yeo L. Atopic dermatitis and the hygiene hypothesis revisited. Curr Probl Dermatol. 2011;41:1–34.
   PubMedGoogle Scholar
• Czarnowicki T, Krueger JG, Guttman-Yassky E. Novel concepts of prevention and treatment of atopic dermatitis through barrier and immune manipulations with implications for the atopic march. J Allergy Clin Immunol. 2017;139:1723–1734.
   PubMed Web of Science ®Google Scholar
• Zaniboni MC, Samorano LP, Orfali RL, et al. Skin barrier in atopic dermatitis: beyond filaggrin. An Bras Dermatol. 2016;91:472–478.
   Google Scholar
• Marenholz I, Nickel R, Ruschendorf F, et al. Filaggrin loss-of-function mutations predispose to phenotypes involved in the atopic march. J Allergy Clin Immunol. 2006;118:866–871.
   PubMed Web of Science ®Google Scholar
• Palmer CN, Irvine AD, Terron-Kwiatkowski A, et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis.[see comment]. Nat Genet. 2006;38:441–446.
   PubMed Web of Science ®Google Scholar
• Sandilands A, Terron-Kwiatkowski A, Hull PR, et al. Comprehensive analysis of the gene encoding filaggrin uncovers prevalent and rare mutations in ichthyosis vulgaris and atopic eczema. Nat Genet. 2007;39:650–654.
   PubMed Web of Science ®Google Scholar
• Sandilands A, Smith FJ, Irvine AD, et al. Filaggrin’s fuller figure: a glimpse into the genetic architecture of atopic dermatitis. J Invest Dermatol. 2007;127:1282–1284.
   PubMed Web of Science ®Google Scholar
• Ching G, Hon KL. Filaggrin null mutations in childhood atopic dermatitis among the Chinese. Int J Immunogenet. 2009;36:251–254.
   PubMed Web of Science ®Google Scholar
• Enomoto H, Hirata K, Otsuka K, et al. Filaggrin null mutations are associated with atopic dermatitis and elevated levels of IgE in the Japanese population: a family and case-control study. J Hum Genet. 2008;53:615–621.
   PubMed Web of Science ®Google Scholar
• Candi E, Schmidt R, Melino G. The cornified envelope: a model of cell death in the skin. Nat Rev Mol Biol. 2005;6:328–340.
   PubMed Web of Science ®Google Scholar
• Krakowski AC, Eichenfield LF, Dohil MA. Management of atopic dermatitis in the pediatric population. Pediatrics. 2008;122:812–824.
   PubMed Web of Science ®Google Scholar
• Jungersted JM, Scheer H, Mempel M, et al. Stratum corneum lipids, skin barrier function and filaggrin mutations in patients with atopic eczema. Allergy. 2010;65:911–918.
   PubMed Web of Science ®Google Scholar
• Hon KL, Lam MC, Leung TF, et al. Clinical features associated with nasal Staphylococcus aureus colonisation in Chinese children with moderate-to-severe atopic dermatitis. Ann Acad Med Singapore. 2005;34:602–605.
   PubMed Web of Science ®Google Scholar
• Hon KL, Tsang KY, Kung JS, et al. Clinical signs, staphylococcus and atopic eczema-related seromarkers. Molecules. 2017;22:E291.
   PubMed Web of Science ®Google Scholar
• Chamlin SL, Frieden IJ, Williams ML, et al. Effects of atopic dermatitis on young American children and their families. Pediatrics. 2004;114:607–611.
   PubMed Web of Science ®Google Scholar
• Hon KL, Leung TF, Wong K, et al. Does age or gender influence quality of life in children with atopic dermatitis? Clin Exp Dermatol. 2008;33:705–709.
   PubMed Web of Science ®Google Scholar
• Ben Gashir MA, Seed PT, Hay RJ. Are quality of family life and disease severity related in childhood atopic dermatitis? J Eur Acad Dermatol Venereol. 2002;16:455–462.
   PubMed Web of Science ®Google Scholar
• Ben Gashir MA. Relationship between quality of life and disease severity in atopic dermatitis/eczema syndrome during childhood. Curr Opin Allergy Clin Immunol. 2003;3:369–373.
   PubMed Web of Science ®Google Scholar
• Ben Gashir MA, Seed PT, Hay RJ. Quality of life and disease severity are correlated in children with atopic dermatitis. Br J Dermatol. 2004;150:284–290.
   PubMed Web of Science ®Google Scholar
• Mooney E, Rademaker M, Dailey R, et al. Adverse effects of topical corticosteroids in paediatric eczema: Australasian consensus statement. Australas J Dermatol. 2015;56:241–251.
   PubMed Web of Science ®Google Scholar
• Coondoo A, Phiske M, Verma S, et al. Side-effects of topical steroids: a long overdue revisit. Indian Dermatol Online J. 2014;5:416–425.
   PubMedGoogle Scholar
• Hon KL, Ying NS, Cheung KL. A tragic case of atopic eczema: malnutrition and infections despite multivitamins and supplements. Iran J Allergy Asthma Immunol. 2012;11:267–270.
   PubMed Web of Science ®Google Scholar
• Grubben C, de CP, Borghgraef M, et al. Severe pre- and postnatal growth retardation, developmental delay with hypotonia and marked hypotrophy of the distal extremities, dental anomalies, and eczematous skin. A new autosomal recessive entity. Clin Genet. 1992;41:16–21.
   PubMed Web of Science ®Google Scholar
• Goustas P, Cork MJ, Higson D. Eumovate (clobetasone butyrate 0.05%) cream: a review of clinical efficacy and safety. J Dermatol Treat. 2003;14:71–85.
   PubMedGoogle Scholar
• Irvine AD, McLean WH. Breaking the (un)sound barrier: filaggrin is a major gene for atopic dermatitis.[see comment]. J Invest Dermatol. 2006;126:1200–1202.
   PubMed Web of Science ®Google Scholar
• Irvine AD, McLean WH, Leung DY. Filaggrin mutations associated with skin and allergic diseases. N Engl J Med. 2011;365:1315–1327.
   PubMed Web of Science ®Google Scholar
• Hon KL, Leung AK, Barankin B. Barrier repair therapy in atopic dermatitis: an overview. Am J Clin Dermatol. 2013;14:389–399.
   PubMed Web of Science ®Google Scholar
• Hon KL, Pong NH, Wang SS, et al. Acceptability and efficacy of an emollient containing ceramide-precursor lipids and moisturizing factors for atopic dermatitis in pediatric patients. Drugs R D. 2013;13:37–42.
   PubMedGoogle Scholar
• Hon KL, Wang SS, Lau Z, et al. Pseudoceramide for childhood eczema: does it work? Hong Kong Med J. 2011;17:132–136.
   PubMedGoogle Scholar
• Hon KL, Kung JSC, Ng WGG, et al. Emollient treatment of atopic dermatitis: latest evidence and clinical considerations. Drugs Context. 2018;7:212530.
   PubMedGoogle Scholar
• Marseglia A, Licari A, Agostinis F, et al. Local rhamnosoft, ceramides and L-isoleucine in atopic eczema: a randomized, placebo controlled trial. Pediatr Allergy Immunol. 2014;25:271–275.
   PubMed Web of Science ®Google Scholar
• Hon KL, Tsang YC, Pong NH, et al. Patient acceptability, efficacy, and skin biophysiology of a cream and cleanser containing lipid complex with shea butter extract versus a ceramide product for eczema. Hong Kong Med J. 2015;21:417–425.
   PubMed Web of Science ®Google Scholar
• Hon KL, Ching GK, Leung TF, et al. Estimating emollient usage in patients with eczema. Clin Exp Dermatol. 2010;35:22–26.
   PubMed Web of Science ®Google Scholar
• Hon KL, Leung AK. Use of ceramides and related products for childhood-onset eczema. Recent Pat Inflamm Allergy Drug Discov. 2013;7(1):12–19.
   Google Scholar
• van Zuuren EJ, Fedorowicz Z, Christensen R, et al. Emollients and moisturisers for eczema. Cochrane Database Syst Rev. 2017;2:CD012119.
   PubMed Web of Science ®Google Scholar
• Lopes C, Silva D, Delgado L, et al. Functional textiles for atopic dermatitis: a systematic review and meta-analysis. Pediatr Allergy Immunol. 2013;24:603–613.
   PubMed Web of Science ®Google Scholar
• Bianchi P, Theunis J, Casas C, et al. Effects of a new emollient-based treatment on skin microflora balance and barrier function in children with mild atopic dermatitis. Pediatr Dermatol. 2016;33:165–171.
   PubMed Web of Science ®Google Scholar
• Cheape AC, Murrell DF. 2% Crisaborole topical ointment for the treatment of mild-to-moderate atopic dermatitis. Expert Rev Clin Immunol. 2017;13:415–423.
   PubMed Web of Science ®Google Scholar
• Paller AS, Tom WL, Lebwohl MG, et al. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults. J Am Acad Dermatol. 2016;75:494–503.
   PubMed Web of Science ®Google Scholar
• Draelos ZD, Stein Gold LF, Murrell DF, et al. Post hoc analyses of the effect of crisaborole topical ointment, 2% on atopic dermatitis: associated pruritus from phase 1 and 2 clinical studies. J Drugs Dermatol. 2016;15:172–176.
   PubMed Web of Science ®Google Scholar
• Zane LT, Chanda S, Jarnagin K, et al. Crisaborole and its potential role in treating atopic dermatitis: overview of early clinical studies. Immunotherapy. 2016;8:853–866.
   PubMed Web of Science ®Google Scholar
• Tom WL, Van SM, Chanda S, et al. Pharmacokinetic profile, safety, and tolerability of crisaborole topical ointment, 2% in adolescents with atopic dermatitis: an open-label phase 2a study. Pediatr Dermatol. 2016;33:150–159.
   PubMed Web of Science ®Google Scholar
• Stein Gold LF, Spelman L, Spellman MC, et al. 2, Randomized, controlled, dose-ranging study evaluating crisaborole topical ointment, 0.5% and 2% in adolescents with mild to moderate atopic dermatitis. J Drugs Dermatol. 2015;14:1394–1399.
   PubMed Web of Science ®Google Scholar
• Murrell DF, Gebauer K, Spelman L, et al. Crisaborole topical ointment, 2% in adults with atopic dermatitis: a phase 2a, vehicle-controlled, proof-of-concept study. J Drugs Dermatol. 2015;14:1108–1112.
   PubMed Web of Science ®Google Scholar
• Simpson E, Udkoff J, Borok J, et al. Atopic dermatitis: emerging therapies. Semin Cutan Med Surg. 2017;36:124–130.
   PubMed Web of Science ®Google Scholar
• Ohba F, Matsuki S, Imayama S, et al. Efficacy of a novel phosphodiesterase inhibitor, E6005, in patients with atopic dermatitis: an investigator-blinded, vehicle-controlled study. J Dermatol Treat. 2016;27:467–472.
   PubMed Web of Science ®Google Scholar
• Hanifin JM, Ellis CN, Frieden IJ, et al. OPA-15406, a novel, topical, nonsteroidal, selective phosphodiesterase-4 (PDE4) inhibitor, in the treatment of adult and adolescent patients with mild to moderate atopic dermatitis (AD): a phase-II randomized, double-blind, placebo-controlled study. J Am Acad Dermatol. 2016;75:297–305.
   PubMed Web of Science ®Google Scholar
• Stevens MT, Edwards AM. The effect of 4% sodium cromoglicate cutaneous emulsion compared to vehicle in atopic dermatitis in children – A meta-analysis of total SCORAD scores. J Dermatol Treat. 2015;26:284–290.
   PubMed Web of Science ®Google Scholar
• Wu SH, Chen XQ, Liu B, et al. Efficacy and safety of 15(R/S)-methyl-lipoxin A(4) in topical treatment of infantile eczema. Br J Dermatol. 2013;168:172–178.
   PubMed Web of Science ®Google Scholar
• Bissonnette R, Papp KA, Poulin Y, et al. Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial. Br J Dermatol. 2016;175:902–911.
   PubMed Web of Science ®Google Scholar
• Nygaard U, Deleuran M, Vestergaard C. Emerging treatment options in atopic dermatitis: topical therapies. Dermatology. 2017;;233(5):333–343.
   Google Scholar
• Lee DE, Clark AK, Tran KA, et al. New and emerging targeted systemic therapies: a new era for atopic dermatitis. J Dermatol Treat. 2017;19:1–11.
   Google Scholar
• Guttman-Yassky E, Dhingra N, Leung DY. New era of biologic therapeutics in atopic dermatitis. Expert Opin Biol Ther. 2013;13:549–561.
   PubMed Web of Science ®Google Scholar
• Wcislo-Dziadecka D, Zbiciak M, Brzezinska-Wcislo L, et al. Anticytokine therapy for psoriasis – not only TNFalpha blockers. Overview of reports on the effectiveness of therapy with IL12/IL23 and T and B lymphocyte inhibitors. Postepy Hig Med Dosw (Online). 2016;70:1198–1205.
   PubMedGoogle Scholar
• Simpson EL, Bieber T, Guttman-Yassky E, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375:2335–2348.
   PubMed Web of Science ®Google Scholar
• Hamilton JD, Ungar B, Guttman-Yassky E. Drug evaluation review: dupilumab in atopic dermatitis. Immunotherapy. 2015;7:1043–1058.
   PubMed Web of Science ®Google Scholar
• Simpson EL, Bieber T, Eckert L, et al. Patient burden of moderate to severe atopic dermatitis (AD): insights from a phase 2b clinical trial of dupilumab in adults. J Am Acad Dermatol. 2016;74:491–498.
   PubMed Web of Science ®Google Scholar
• Thaci D, Simpson EL, Beck LA, et al. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial. Lancet. 2016;387:40–52.
   PubMed Web of Science ®Google Scholar
• Tsianakas A, Luger TA. The anti-IL-4 receptor alpha antibody dupilumab: facing a new era in treating atopic dermatitis. Expert Opin Biol Ther. 2015;15:1657–1660.
   PubMed Web of Science ®Google Scholar
• Simpson EL, Gadkari A, Worm M, et al. Dupilumab therapy provides clinically meaningful improvement in patient-reported outcomes (PROs): a phase IIb, randomized, placebo-controlled, clinical trial in adult patients with moderate to severe atopic dermatitis (AD). J Am Acad Dermatol. 2016;75:506–515.
   PubMed Web of Science ®Google Scholar
• Mullard A. FDA approves dupilumab for severe eczema. Nat Rev Drug Discov. 2017;16:305.
   Web of Science ®Google Scholar
• [cited June 20 2018]. Available from: https://www.mdedge.com/edermatologynews/article/133798/atopic-dermatitis/dupilumab-improved-eczema-scores-children-open.
   Google Scholar
• Wang HH, Li YC, Huang YC. Efficacy of omalizumab in patients with atopic dermatitis: a systematic review and meta-analysis. J Allergy Clin Immunol. 2016;138:1719–1722.
   PubMed Web of Science ®Google Scholar
• Vashisht P, Casale T. Omalizumab for treatment of allergic rhinitis. Expert Opin Biol Ther. 2013;13:933–945.
   PubMed Web of Science ®Google Scholar
• Saito S, Aoki A, Arai I, et al. Regulation of Th2 responses by different cell types expressing the interleukin-31 receptor. Allergy Asthma Clin Immunol. 2017;13:23.
   PubMed Web of Science ®Google Scholar
• Ruzicka T, Hanifin JM, Furue M, et al. Anti-interleukin-31 receptor A antibody for atopic dermatitis. N Engl J Med. 2017;376:826–835.
   PubMed Web of Science ®Google Scholar
• Kasraie S, Niebuhr M, Baumert K, et al. Functional effects of interleukin 31 in human primary keratinocytes. Allergy. 2011;66:845–852.
   PubMed Web of Science ®Google Scholar
• Levy LL, Urban J, King BA. Treatment of recalcitrant atopic dermatitis with the oral Janus kinase inhibitor tofacitinib citrate. J Am Acad Dermatol. 2015;73:395–399.
   PubMed Web of Science ®Google Scholar
• Murata Y, Song M, Kikuchi H, et al. Phase 2a, randomized, double-blind, placebo-controlled, multicenter, parallel-group study of a H4 R-antagonist (JNJ-39758979) in Japanese adults with moderate atopic dermatitis. J Dermatol. 2015;42:129–139.
   PubMed Web of Science ®Google Scholar
• Lloyd-Lavery A, Rogers NK, Hatfield SJ, et al. What’s new in atopic eczema? An analysis of systematic reviews published in 2014. Part 2. Treatment and prevention. Clin Exp Dermatol. 2017;42:3–7.
   PubMed Web of Science ®Google Scholar
• Gendelman SR, Lang DM. Sublingual immunotherapy in the treatment of atopic dermatitis: a systematic review using the GRADE system. Curr Allergy Asthma Rep. 2015;15:498–0498.
   PubMed Web of Science ®Google Scholar
• Kim MJ, Kim SN, Lee YW, et al. Vitamin D status and efficacy of vitamin D supplementation in atopic dermatitis: a systematic review and meta-analysis. Nutrients. 2016;8:E789.
   PubMed Web of Science ®Google Scholar
• Kim G, Bae JH. Vitamin D and atopic dermatitis: a systematic review and meta-analysis. Nutrition. 2016;32:913–920.
   PubMed Web of Science ®Google Scholar
• Chang YS, Lin MH, Lee JH, et al. Melatonin supplementation for children with atopic dermatitis and sleep disturbance: a randomized clinical trial. JAMA Pediatr. 2016;170:35–42.
   PubMed Web of Science ®Google Scholar
• Hon KL, Chan BC, Leung PC. Chinese herbal medicine research in eczema treatment. Chinesische Medizin. 2011;6:17.
   PubMed Web of Science ®Google Scholar
• Hon KL, Leung TF, Yau HC, et al. Paradoxical use of oral and topical steroids in steroid-phobic patients resorting to traditional Chinese medicines. World J Pediatr. 2012;8:263–267.
   PubMed Web of Science ®Google Scholar
• Hon KL, Leung AKC, Leung TNH, et al. Complementary, Alternative and Integrative medicine for childhood atopic dermatitis. Recent Pat Inflamm Allergy Drug Discov. 2017;11(2):114–124.
   Web of Science ®Google Scholar
• Zhang S, Zeng X, Wei J, et al. Analysis of trends and opportunities of anti-allergy patents in China from 1998 to 2008. Recent Pat Inflamm Allergy Drug Discov. 2010;4:130–137.
   PubMedGoogle Scholar
• Boneberger S, Rupec RA, Ruzicka T. Complementary therapy for atopic dermatitis and other allergic skin diseases: facts and controversies. Clin Dermatol. 2010;28:57–61.
   PubMed Web of Science ®Google Scholar
• Fung AY, Look PC, Chong LY, et al. A controlled trial of traditional Chinese herbal medicine in Chinese patients with recalcitrant atopic dermatitis. Int J Dermatol. 1999;38:387–392.
   PubMed Web of Science ®Google Scholar
• Johnstong G, Bilbaor R, Graham-Brown R, et al. The use of complementary medicine in children with atopic dermatitis in secondary care in Leicester. Br J Dermatol. 2003;149:566–571.
   PubMed Web of Science ®Google Scholar
• Zhang W, Leonard T, Bath-Hextall F, et al. Chinese herbal medicine for atopic eczema. Update Cochrane Database Syst Rev. 2004;(4):CD002291. PMID: 15495031. 2005.
   Google Scholar
• Gu S, Yang AW, Xue CC, et al. Chinese herbal medicine for atopic eczema. Cochrane Database Syst Rev. 2013;9:CD008642.
   PubMed Web of Science ®Google Scholar
• Gu S, Yang AW, Li CG, et al. Topical application of Chinese herbal medicine for atopic eczema: a systematic review with a meta-analysis. Dermatology. 2014;228:294–302.
   PubMed Web of Science ®Google Scholar
• Sheehan MP, Atherton DJ. A controlled trial of traditional Chinese medicinal plants in widespread non-exudative atopic eczema. Br J Dermatol. 1992;126:179–184.
   PubMed Web of Science ®Google Scholar
• Sheehan MP, Atherton DJ. One-year follow up of children treated with Chinese medicinal herbs for atopic eczema. Br J Dermatol. 1994;130:488–493.
   PubMed Web of Science ®Google Scholar
• Sheehan MP, Stevens H, Ostlere LS, et al. Follow-up of adult patients with atopic eczema treated with Chinese herbal therapy for 1 year. Clin Exp Dermatol. 1995;20:136–140.
   PubMed Web of Science ®Google Scholar
• Hon K-L, Leung T-F, Wong Y, et al. A pentaherbs capsule as a treatment option for atopic dermatitis in children: an open-labeled case series. Am J Chin Med. 2004;32:941–950.
   PubMed Web of Science ®Google Scholar
• Hon KL, Lee VW, Leung TF, et al. Corticosteroids are not present in a traditional Chinese medicine formulation for atopic dermatitis in children. Ann Acad Med Singapore. 2006;35:759.
   PubMed Web of Science ®Google Scholar
• Hon KL, Leung TF, Ng PC, et al. Efficacy and tolerability of a Chinese herbal medicine concoction for treatment of atopic dermatitis: a randomized, double-blind, placebo-controlled study. Brit J Dermatol. 2007;157(2):357–363.
   Web of Science ®Google Scholar
• Bai YP, Yang DQ, Wang YM. [Clinical study on treatment of acute eczema by Shuangfujin]. [Chinese]. iZhongguo Zhong Xi Yi Jie He Za Zhi Zhongguo Zhongxiyi Jiehe Zazhi/Chin J Integr Traditional West Med/Zhongguo Zhong Xi Yi Jie He Xue Hui, Zhongguo Zhong Yi Yan Jiu Yuan Zhu Ban. 2007;27:72–75.
   PubMedGoogle Scholar
• Kobayashi H. [Clinical evaluation of Hochuekkito in the treatment of atopic dermatitis: a multicenter, double-blind, randomized, placebo-controlled study]. [Japanese]. Nippon Yakurigaku Zasshi – Folia Pharmacologica Japonica. 2008;132:285–287.
   PubMedGoogle Scholar
• Kobayashi H. [Clinical evaluation of Hochuekkito in the treatment of atopic dermatitis: a multicenter, double-blind, randomized, placebo-controlled study]. Nihon Yakurigaku Zasshi. 2008;132:285–287.
   PubMedGoogle Scholar
• Cheng HM, Chiang LC, Jan YM, et al. The efficacy and safety of a Chinese herbal product (Xiao-Feng-San) for the treatment of refractory atopic dermatitis: a randomized, double-blind, placebo-controlled trial. Int Arch Allergy Immunol. 2011;155:141–148.
   PubMed Web of Science ®Google Scholar
• Hon KL, Ma KC, Wong Y, et al. A survey of traditional Chinese medicine use in children with atopic dermatitis attending a paediatric dermatology clinic. J Dermatolog Treat. 2005;16:154–157.
   PubMed Web of Science ®Google Scholar
• Hon K, Kam WY, Lam M, et al. CDLQI, SCORAD and NESS: are they correlated? Qual Life Res. 2006;15:1551–1558.
   PubMed Web of Science ®Google Scholar
• Ernst E. Homeopathy for eczema: a systematic review of controlled clinical trials. Br J Dermatol. 2012;166:1170–1172.
   PubMed Web of Science ®Google Scholar